4/8/2008
Airway inflammation measurement receives reimbursement in Czech Republic
SOLNA, Sweden – 8 April, 2008 – Aerocrine AB (OMX Nordic Exchange: AERO) today announced that a new reimbursement code has been issued for the exhaled NO tests in the Czech healthcare system.
3/20/2008
Aerocrine files patent infringement suit against Medisoft in Germany
SOLNA, Sweden – 20 March 2008 – Aerocrine AB (OMX Nordic Exchange: AERO) today announced the filing with the District Court of Dusseldorf of a Complaint and Motion to prevent Medisoft, P.A.E from marketing and selling its exhaled Nitric Oxide (NO) analyser in Germany. The claim seeks both an injunction and damages.
3/4/2008
FDA Grants Market Clearance to Aerocrine Inc.’s NIOX MINO®: a New Hand-Held Device to Measure Airway Inflammation in Asthma
NIOX MINO® Set to Dramatically Improve Airway Inflammatory Disease Management through Personalized Inflammation Control.
NEW PROVIDENCE, N.J., March 4, 2008 – Aerocrine, Inc. today announced that NIOX MINO, a hand-held point-of-care device for the measurement of airway inflammation, has been 510(k) cleared by the U.S. Food and Drug Administration (FDA). Physicians in the U.S. now have a highly accurate, non-invasive and convenient technology that is appropriate for use in a doctor’s office, ultimately helping them improve how they treat asthma patients.
2/11/2008
Aerocrine enters distribution agreement with Chest in Japan
SOLNA – February 11, 2008 – Aerocrine AB (OMX Nordic Exchange: AERO) announces that the company has entered into a distribution agreement with Chest M.I. Inc. Chest will market and sell NIOX MINO® in Japan.
2/7/2008
Aerocrine appoints new President of Aerocrine Inc.
SOLNA, Sweden – 7 February, 2008 – Aerocrine AB (OMX Nordic Exchange: AERO) today announced the appointment of Chip Neff to the position of President of Aerocrine’s US subsidiary Aerocrine Inc., effective from 25 February 2008. Chip Neff will succeed Trevor Bourke, who has led the development of Aerocrine Inc since 2002. Trevor Bourke will remain at Aerocrine Inc during the transition, prior to taking up a new role in Europe.
1/14/2008
Cost savings in asthma management when using NIOX MINO® First health economic study published
SOLNA – 14 January, 2008 – Aerocrine AB (OMX Nordic Exchange: AERO) reports that the first heath economic study evaluating the effect of introducing measurements of exhaled NO in asthma management has been published.
1/9/2008
Aerocrine strengthens its patent portfolio
SOLNA – 9 January 2008 – Aerocrine AB (OMX Nordic Exchange: AERO) announces that the company has strengthened its patent portfolio by both acquiring a strategically important patent and patenting its own discoveries.
12/20/2007
Aerocrine enters distribution agreement with Phadia in France
SOLNA – 20 December, 2007 – Aerocrine AB (OMX Nordic Exchange: AERO) announces that the company has entered into a distribution agreement with Phadia France.
12/7/2007
NIOX® approved in China. Aerocrine expands its distribution agreement to include NIOX MINO®.
SOLNA – 7 December 2007 – Aerocrine AB (OMX Nordic Exchange: AERO) announces that the company’s NIOX product has been approved by SFDA, the Chinese registration authority. Aerocrine has also entered into a distribution agreement with Bioson Inc. that includes sales of both NIOX and NIOX MINO in China.
10/15/2007
Aerocrine enters collaboration for improved treatment of asthma and intestinal diseases
SOLNA – 15 October, 2007 – Aerocrine AB (OMX Nordic Exchange: AERO) announces that it has become a partner in a program for the development of diagnostic methods for allergies, asthma and food hypersensitivity.
10/2/2007
Aerocrine submits 510(k) filing for NIOX MINO® in the U.S.
SOLNA – October 2, 2007 – Aerocrine AB (OMX Nordic Exchange: AERO) announced that it has submitted a 510(k) application for marketing clearance to the U.S. Food & Drug Administration (FDA) for its NIOX MINO® device.
9/17/2007
Aerocrine appoints Vice President Global Sales
SOLNA – 17 September, 2007 – Aerocrine appoints new senior sales position whereby Anna Malm Bernsten joins Aerocrine's management team from mid September with the responsibility for global sales.
8/24/2007
AEROCRINE REINFORCES MANAGEMENT TEAM
SOLNA, Stockholm – 24th of August 2007 – In August Kjell Alving, Professor at the Karolinska Institute, joined Aerocrine’s management team responsible for scientific and medical affairs.
1/25/2007
AEROCRINE APPOINTS NEW CEO
SOLNA, Sweden -- Jan. 25, 2007 -- Aerocrine today announced the appointment of Paul de Potocki to the position of President and Chief Executive Officer, Aerocrine AB, effective from February 1, 2007. Paul succeeds Thomas Almesjö who has led the development of Aerocrine since its foundation, and who is now moving on to assignments outside the company.
9/30/2006
Swedish asthma-instrument launched into space: How much dust does an astronaut eat?
A novel instrument developed to help asthma patients is about to be launched to the International Space Station (ISS) in the frame of the European exploitation programme run by the European Space Agency (ESA). The instrument will be used to support scientific investigations on the effect of inhalation of dust particles and lung performances after space walks outside the station.
5/1/2003
A first-of-a-kind, non-invasive test to monitor asthma - NIOX cleared by the FDA